secwatch / observer
8-K filed March 9, 2023, 6:59 PM ET ticker SFES CIK 0000086115
earnings confidence high sentiment negative materiality 0.75

Safeguard Scientifics posts FY2022 net loss of $14.3M vs net income of $27.0M in 2021

SAFEGUARD SCIENTIFICS INC

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SAFEGUARD SCIENTIFICS INC reported three months and year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $14.3 million, or $0.87 per share, EPS $0.87 per share.

Period
three months and year ended December 31, 2022
Net income
Net loss for the year ended December 31, 2022 was $14.3 million, or $0.87 per share
EPS
$0.87 per share
Result
reported results
Exact text from the filing
Net loss for the three months ended December 31, 2022 was $4.9 million, or $0.30 per share, compared with a net loss of $8.6 million, or $0.51 per share, for the same period in 2021.
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SAFEGUARD SCIENTIFICS INC reported three months and year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $14.3 million, or $0.87 per share, EPS $0.87 per share.

Period
three months and year ended December 31, 2022
Net income
Net loss for the year ended December 31, 2022 was $14.3 million, or $0.87 per share
EPS
$0.87 per share
Result
reported results
Exact text from the filing
Net loss for the year ended December 31, 2022 was $14.3 million, or $0.87 per share, compared with net income of $27.0 million, or $1.36 per share, for the same period of 2021.
View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

SAFEGUARD SCIENTIFICS INC filing history →

Source: SEC EDGAR
accession 0001437749-23-005972
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.